Table 5.
12‐lead ECG results: mean values and change from baseline at EoT (assessment by central reader)
| Mean (SD) | |||
|---|---|---|---|
| Combination (n=725) | Solifenacin 5 mg (n=728) | Solifenacin 10 mg (n=719) | |
| PR duration (mseconds) | |||
| Baseline | 165.62 (23.08) [n=713] | 165.18 (24.02) [n=722] | 165.15 (22.89) [n=714] |
| EoT | 165.52 (22.91) [n=703] | 165.48 (23.57) [n=710] | 166.20 (22.49) [n=704] |
| Change from baseline | 0.08 (11.82) [n=699] | 0.48 (11.97) [n=708] | 0.95 (10.67) [n=704] |
| RR duration (mseconds) | |||
| Baseline | 894.20 (131.01) [n=721] | 891.15 (136.96) [n=727] | 892.71 (123.71) [n=719] |
| EoT | 870.00 (123.13) [n=710] | 877.50 (136.25) [n=714] | 880.70 (130.68) [n=709] |
| Change from baseline | −23.07 (102.39) [n=707] | −13.34 (106.44) [n=713] | −12.29 (102.12) [n=709] |
| QRS duration (mseconds) | |||
| Baseline | 92.92 (9.58) [n=721] | 92.74 (10.10) [n=727] | 92.46 (8.60) [n=719] |
| EoT | 93.71 (9.88) [n=710] | 93.48 (9.81) [n=714] | 93.47 (8.82) [n=709] |
| Change from baseline | 0.82 (5.19) [n=707] | 0.73 (6.10) [n=713] | 0.98 (6.23) [n=709] |
| QTcF (mseconds) | |||
| Baseline | 417.34 (18.00) [n=721] | 416.52 (18.09) [n=727] | 415.42 (17.85) [n=719] |
| EoT | 417.85 (18.99) [n=710] | 417.35 (17.67) [n=714] | 418.77 (19.01) [n=709] |
| Change from baseline | 0.49 (13.23) [n=707] | 0.77 (12.98) [n=713] | 3.30 (13.72) [n=709] |
| Heart rate (bpm) | |||
| Baseline | 68.61 (9.90) [n=721] | 69.03 (10.53) [n=727] | 68.63 (9.73) [n=719] |
| EoT | 70.41 (9.77) [n=710] | 70.13 (10.84) [n=714] | 69.73 (10.43) [n=709] |
| Change from baseline | 1.71 (8.19) [n=707] | 1.08 (8.65) [n=713] | 1.12 (8.22) [n=709] |
EoT, end of treatment; QTcF, QT interval corrected using Fridericia's formula.